Arena Pharmaceuticals, Inc. (ARNA) Posts Q2 Loss of 12c/Share, Wider than Views
Get Alerts ARNA Hot Sheet
Price: $99.98 --0%
Financial Fact:
Total operating expenses: 29.1M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Financial Fact:
Total operating expenses: 29.1M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Join SI Premium – FREE
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) reported Q2 EPS of ($0.12), $0.04 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $22 million versus the consensus estimate of $7.38 million.
For earnings history and earnings-related data on Arena Pharmaceuticals, Inc. (ARNA) click here.
For earnings history and earnings-related data on Arena Pharmaceuticals, Inc. (ARNA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- Southern Copper Corp. (SCCO) Tops Q1 EPS by 20c
- First Resource Bank (FRSB) Tops Q1 EPS by 43c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!